MIDLOTHIAN, Va., Oct. 12 /PRNewswire/ -- PARI Respiratory Equipment’s LC Plus Reusable Nebulizer and mobile compressors were exclusively used as the aerosol delivery system to develop Sepracor’s Brovana Inhalation Solution that was approved Friday by the Food and Drug Administration for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, COPD. Brovana is the only nebulized long-acting beta 2 agonist approved as a long term maintenance treatment for COPD and is delivered by nebulizer twice a day as prescribed by physicians.
Brovana, arformoterol tartrate, is the first long-acting bronchodilator to be developed in an inhalation solution for use with a nebulizer, which is a machine that converts liquid medication into a fine mist that is inhaled through a mouthpiece or mask. Other long-acting bronchodilators currently available in the U.S. are formulated in dry-powder inhalers.
“PARI has a great history working with drug development companies to develop new and improved medications to enhance people’s lives. We are pleased that Sepracor’s Brovana was developed with PARI’s LC Plus and mobile nebulizers and believe that patients will appreciate the short six minute treatment times,” said Werner Gutmann, president of PARI Respiratory Equipment. “We believe the combination of Sepracor’s Brovana and PARI’s advanced aerosol delivery devices will truly better the lives of COPD sufferers.”
Treatment times with PARI’s LC Plus, a breath-enhanced, reusable nebulizer when used in combination with the PARI TREK Compact Compressor System, are six minutes or less. The TREK is a small, portable compressor that enables patients to take treatments anywhere. It has a rechargeable battery that lasts up to 60 minutes and comes with a convenient carrying case. PARI’s LC Plus has been the leading breath-enhanced nebulizer on the market for the last 10 years. PARI’s DURA-NEB 3000 and TREK Compact Compressor System with the LC PLUS Reusable Nebulizer were used exclusively in Sepracor’s clinical trials to gain market approval for Brovana Inhalation Solution.
About COPD
COPD is a pulmonary disease that is characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema. While it may be partially reversible, there is no cure for COPD. In 2004, the National Center for Health Statistics estimated 11.4 million U.S. adults had COPD.
About Sepracor
Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing, and commercializing innovative pharmaceutical products that are directed toward serving unmet medical needs. In addition to Brovana, Sepracor currently commercializes three proprietary products: LUNESTA(R) (eszopiclone) for the treatment of insomnia; XOPENEX HFA(R) (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler (MDI); and XOPENEX(R) (levalbuterol HCl) Inhalation Solution. Online at www.sepracor.com.
About PARI Respiratory Equipment
PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI’s worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them. Maker of the world’s leading breath-enhanced reusable nebulizer, the PARI LC PLUS, PARI also manufacturers the award winning PARI TREK compact compressor, the innovative aerosol mask Bubbles the Fish II, and powerful PARI PRONEB Ultra II and Max. PARI’s North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at www.Pari.com
Additional information is available by contacting Lisa Cambridge at 978-768-7662 or Ayars & Associates at 805-566-2986.
PARI Respiratory Equipment
CONTACT: Lisa Cambridge, +1-978-768-7662; or Ayars & Associates,+1-805-566-2986, both for PARI Respiratory Equipment
